

Thyroid cancer Committee meeting 14

Date: 19/1/22 10:00-16:00

Location: Virtual meeting

Minutes: Confirmed

Committee members present:		
Richard Grünewald [RG] – Chair		(Present for notes 1 – 8)
Jeremy Davis [JD] – Topic advisor		(Present for notes 1 – 8)
John Buscombe [JB]		(Present for notes 1 – 8)
Preetha Chengot [PC]		(Present for notes 1 – 8)
Neil Cozens [NC]		(Present for notes 1 – 8)
Fiona Eatock [FE]		(Present for notes 1 – 8)
Kate Farnell [KF]		(Present for notes 1 – 8)
Steve Hyer [SHY]		(Present for notes 1 – 8)
Jessica Lishak [JL]		(Present for notes 1 – 8)
Kate Newbold [KN]		(Present for notes 1 – 8)
Iain Nixon [IN]		(Present for notes 1 – 8)
Sonja Hoy [SH]		(Present for notes 1 – 8)
Anh Tran [AT]		(Present for notes 1 – 8)
Nicholas Reed [NR]		(Present for notes 1 – 8)

In attendance:		
Carlos Sharpin [CS]	Guideline Lead	(Present for notes 1 – 8)
Catrina Charlton	NICE Guideline Commissioning Manager	(Present for notes 3 – 6)
Mark Perry [MP]	Senior Research Fellow	(Present for notes 1 – 8)
Alfredo Mariani [AM]	Health Economist	(Present for notes 1 – 8)

Apologies:	
Jessica Lishak [JL]	Lay Member
Lina Gulhane [LG]	Head of Information Specialists

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the fourteenth meeting on Thyroid cancer. The Committee members and attendees introduced themselves.

The Chair outlined the objectives of the meeting, which included:

- FNAC
- Ultrasound diagnosis
- Molecular testing
- Economic modelling

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were FNAC, ultrasound diagnosis, rapid onsite assessment, molecular testing, blood tests.

There were no new declarations of interest.

The Chair and a senior member of the Developer's team noted that the interests previously declared did not prevent the attendees from fully participating in the meeting.

3. Clinical evidence reruns: FNAC

MP confirmed that although 5 new papers were found during the reruns, they did not change the results and therefore the FNAC recommendations did not need to be amended.

4. Clinical evidence reruns: Ultrasound diagnosis

MP presented new evidence relating to the diagnostic accuracy of ultrasound. The committee discussed different diagnostic systems and thresholds. Updates were made to the recommendations, in light of the new evidence.

5. Economic reruns

AM presented new economic evidence relating to rapid on-site assessment and molecular testing. The evidence was in line with the previously found evidence, economic analysis and recommendations; therefore the existing recommendations

did not need to be amended.

6. Recommendations

The following recommendations were revisited and reviewed:

- Thyroid antibody blood tests, and serum calcitonin
- Radioisotope scans
- Molecular testing
- FNAC and repeat FNAC

7. Economic model

AM presented an update on the economic model. The committee provided feedback. The recommendations were also reviewed in line with the economic model. The model will be finalised and an update provided at the next meeting.

8. Any other business

CS informed the committee that the recommendations would be added to the short guideline and sent to NICE. This will then be circulated to the committee once feedback and edits are received.

CS explained that an algorithm will be created. IN and FE volunteered to provide input.

The committee agreed to the next meeting running longer; from 09:30-16:30.

Date of next meeting:

16 February 2022

Location of next meeting: Virtual meeting